Evaluating Hypertonic Saline Solution to Prevent Kidney Injury After Heart Transplantation

What this Trial Is About

Researchers are evaluating whether hypertonic saline solution can prevent or lessen acute kidney injury AKI shortly after heart transplantation. AKI is a common complication within the first days after this surgery, affecting 40-70% of patients due to factors like excess fluid, hormone system activation, and low heart output. This Phase 2 randomized study aims to explore if hypertonic saline can improve kidney outcomes in this critical period after heart transplant. Participants will be randomly assigned to receive either 150 mL of hypertonic saline solution 3.5% or a placebo normal saline solution 0.9% intravenously twice daily for three days following the heart transplant. The study compares these two treatments to see their effects on kidney function and heart performance. Patients will be monitored closely for 30 days or until death. During the study, kidney function, echocardiograms of the right heart, and measurements from pulmonary artery catheters will be assessed. Researchers will track outcomes such as the occurrence of acute kidney injury by days 3 to 7 post-transplant, mortality within 30 days, need for dialysis, time spent in intensive care, heart function, and response to diuretics. This detailed monitoring helps evaluate the impact of the treatment on early post-transplant recovery and kidney protection.

Hypertonic Saline Solution to Prevent Acute Kidney Injury After Heart Transplantation